- 1117.488
- -8.383-0.74%
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
J.P. Morgan Keeps Their Sell Rating on Roche Holding AG (RHHVF)
Evercore Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Quest Diagnostics: Hold Rating Affirmed Amid Balanced Risk/Reward Profile and Premium Valuation
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Quest Diagnostics Analyst Ratings
Hold Rating on Abbott Laboratories Amid NEC Litigation Uncertainties
Jefferies Maintains Abbott Laboratories(ABT.US) With Hold Rating, Raises Target Price to $120
Barclays Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $154
Barclays Remains a Hold on Quest Diagnostics (DGX)
Barclays Raises Quest Diagnostics' Price Target to $154 From $144, Maintains Equalweight Rating
BTIG Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135
Emergent Biosolutions Price Target Announced at $16.00/Share by Rodman & Renshaw
Emergent BioSolutions Analyst Ratings
Abbott Laboratories Analyst Ratings
Rodman & Renshaw Upgrades Emergent BioSolutions(EBS.US) to Buy Rating, Cuts Target Price to $16
Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $127
Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78